Galmed Pharmaceuticals
GLMD
20 hedge funds and large institutions have $5.93M invested in Galmed Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 2 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
1% less capital invested
Capital invested by funds: $5.99M → $5.93M (-$60K)
5% less funds holding
Funds holding: 21 → 20 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$54.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$27.1K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$23.9K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$19.2K |
| 5 |
MC
Menta Capital
San Francisco,
California
|
+$9.58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$169K |
| 2 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$166K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$24K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$14.4K |
| 5 |
Morgan Stanley
New York
|
-$3.19K |
GLMD Hedge Fund Activity: Q4 2015 in Review
20 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q4 2015, worth a combined $5.93M — down 1% from $5.99M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of GLMD and 1 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 5 added.
The largest buyer was DAFNA Capital Management, adding an estimated $54.3K. The largest seller was Goldman Sachs, cutting an estimated $169K.
- 20 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q4 2015, down from 21 in Q3 2015.
- Funds reported $5.93M of Galmed Pharmaceuticals stock for Q4 2015, down 1% quarter-over-quarter.
- 1 fund opened new Galmed Pharmaceuticals positions in Q4 2015 and 2 closed out, a net change of -1 holder.
- The largest Galmed Pharmaceuticals buyer in Q4 2015 was DAFNA Capital Management, an estimated $54.3K added.
- The largest Galmed Pharmaceuticals seller in Q4 2015 was Goldman Sachs, an estimated $169K sold.
Based on aggregated 13F filings for Q4 2015.